Carolina Digestive Diseases

Greenville, North Carolina 27834-3761

1 studies enrolling now · 14 studies all time

What they study most

Celiac Disease, Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Diabetic Gastroparesis, Gastroesophageal Reflux Disease (GERD), Idiopathic Gastroparesis, Irritable Bowel Syndrome, NASH - Nonalcoholic Steatohepatitis, Ulcerative Colitis

Studies at this site

• A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting — Recruiting now
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) — Stopped early
• An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice — Stopped early
• A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease — Stopped early
• A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis — Completed
• A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet — Completed
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease — Stopped early
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC) — Completed
• A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease — Completed
• Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) — Completed
• Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome — Completed
• LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) — Completed